IM-1021 not checked

Immunome, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total · 1 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Solid Malignancies, Hematologic Malignancies
Main trialPhase 1
“IM-1021-101 is a Phase 1 study to determine the safety and effectiveness of IM-1021 in treating participants with advanced cancer.”In the company’s words, NCT06823167 on ClinicalTrials.gov

Other drugs for Solid Malignancies

All 302 drugs for Solid Malignancies

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Recruiting May 2028 A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow IM-1021

Following is part of Solo: you see every change to IM-1021 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in